PFE
Pfizer Inc.
Healthcare · Drug Manufacturers - General · United States · Stock
Score Breakdown
Scored for Safe Long-Term Investing profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- The model score of 50.2/100 is anchored by two meaningful sub-scores — financial health at 16.0/20 and momentum at 15.0/20 — which together reflect a financially solvent company with improving near-term operating trends, preventing the score from falling into a lower tier.
- Profitability at 10.8/20 and growth at 5.0/20 drag the composite score toward the midpoint, reflecting real filing-period weaknesses in margin structure and year-over-year expansion metrics that offset the balance sheet and momentum strengths.
- The dividend sub-score of 6.2/20 adds modest incremental points but underperforms relative to what would be expected from a company of Pfizer's historical dividend-paying stature, contributing to the score landing at 50.2 rather than meaningfully higher.
Why Not Higher
- The growth sub-score of 5.0/20 is the primary ceiling constraint — without stronger year-over-year revenue and earnings expansion, the model cannot award points in the dimension that typically drives high composite scores, and Pfizer's post-COVID revenue contraction is directly penalizing this metric.
- The theme score of 0.0/20 represents a complete absence of contribution from macro theme exposure, meaning Pfizer is missing up to 20 points that companies with identifiable thematic tailwinds (such as AI-driven drug discovery or GLP-1/obesity) would receive, which structurally limits the total score under the current model version.
Data Confidence
10 / 10
Very High — full data coverage
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Pfizer Inc. is one of the world's largest biopharmaceutical companies, headquartered in New York, engaged in the discovery, development, manufacture, and commercialization of medicines and vaccines across therapeutic areas including oncology, immunology, cardiovascular disease, and infectious disease. The company's model score of 50.2/100 reflects a mixed financial picture drawn from its FY 2025 10-K filing: its financial health sub-score of 16.0/20 stands out as a relative strength, indicating manageable leverage and reasonable interest coverage on a large balance sheet, while momentum scores a solid 15.0/20, suggesting meaningful sequential improvement in revenue, earnings, or margins across recent quarters. However, profitability scored only 10.8/20 — pointing to compressed net and operating margins, likely reflecting the significant post-COVID revenue normalization Pfizer has undergone as Paxlovid and Comirnaty demand declined from peak levels — and growth scored a low 5.0/20, indicating weak year-over-year revenue, net income, and EPS trends in the filing period. The dividend sub-score of 6.2/20 raises questions about free cash flow coverage of the dividend, even as Pfizer has historically been a dividend-focused company. The theme score of 0.0/20 suggests the model did not identify meaningful exposure to scored macro themes in the filing data. The central research tradeoff for Pfizer is between its durable institutional scale — a vast manufacturing infrastructure, deep pipeline, and recently expanded oncology portfolio following the Seagen acquisition — and its near-term financial headwinds from post-pandemic revenue contraction and elevated costs. The model's best-fit profile is safe long-term investing (52.4), modestly above the overall score, which aligns with Pfizer's historical positioning as a dividend-paying large-cap pharma rather than a high-growth compounder. Researchers evaluating PFE should weigh whether the current operational momentum (15.0/20) represents a genuine inflection point or a temporary stabilization within a prolonged reset period.
Plain English
Pfizer is a giant pharmaceutical company that makes drugs and vaccines — you may know them from COVID-19 vaccines and treatments. The model scored it 50.2 out of 100, which is right in the middle, meaning it has some real strengths like a healthy balance sheet and improving quarterly results, but also real weaknesses like slow revenue growth and thinner profit margins compared to its historical norms. The Medium risk rating reflects that this is a large, established company that isn't going to disappear, but it faces meaningful uncertainty around whether its newer products and pipeline can replace the revenue it lost when COVID-related sales dropped sharply. It earns a 'Research Further' label, meaning the data suggests it warrants a closer look rather than a clear directional signal.
Bull Case vs. Bear Case
Bull Case
- The financial health sub-score of 16.0/20 indicates that Pfizer maintains a robust balance sheet with manageable leverage and sufficient interest coverage, providing a stable foundation even during a revenue reset period.
- The momentum sub-score of 15.0/20 — the second-highest sub-score in the model — signals that Pfizer's quarterly revenue, earnings, or margin trends are showing material sequential improvement, which could indicate the business is beginning to stabilize or recover from post-pandemic normalization.
- Pfizer's expanded oncology portfolio following the Seagen acquisition represents a structural pipeline catalyst that is not yet fully reflected in the growth sub-score, and continued uptake of Padcev, Adcetris, and other oncology assets could drive meaningful revenue contribution in future filing periods.
Bear Case
- The growth sub-score of just 5.0/20 reflects weak year-over-year revenue, net income, and EPS performance in the FY 2025 filing, underscoring that Pfizer has not yet replaced the peak COVID-era revenue stream with equivalent non-COVID product revenue.
- The profitability sub-score of 10.8/20 suggests that net margins, operating margins, and return on assets remain below levels that would characterize a highly efficient pharmaceutical operator, likely reflecting elevated cost structures from post-acquisition integration and ongoing R&D investment.
- The dividend sub-score of 6.2/20 raises concerns about free cash flow coverage of the dividend payout, meaning the sustainability of Pfizer's dividend — a core component of its long-term investor appeal — may be under strain in the current financial environment.
What Could Change the Picture
Bullish Triggers
- A meaningful improvement in the growth sub-score in a subsequent filing — driven by sustained non-COVID revenue growth from the oncology portfolio, new product launches, or positive pipeline readouts translating into approved revenues — would materially strengthen the research case.
- Demonstrated improvement in the dividend sub-score through stronger free cash flow generation and evidence of sustainable dividend coverage would reinforce Pfizer's positioning for the safe long-term investing goal profile and could push the composite score above 55.
Bearish Triggers
- A deterioration in the financial health sub-score — for example, if leverage increased materially due to additional large acquisitions or if interest coverage declined — would undermine the most reliable pillar supporting the current model score.
- If the momentum sub-score declined in a future filing period, reversing the current sequential improvement signal, it would suggest the recent stabilization was temporary and that the underlying business has not yet found a durable growth floor, weakening the research case significantly.
Red Flags
- The dividend sub-score of 6.2/20 is low enough to suggest that free cash flow coverage of the dividend may be inadequate, which is a material concern for a company whose investment thesis has historically centered on reliable income generation.
- The growth sub-score of 5.0/20 in combination with a low profitability sub-score of 10.8/20 indicates that Pfizer is neither growing strongly nor generating high-quality margins, raising questions about how quickly the business can return to financial productivity following the Seagen integration and COVID revenue decline.
- The theme score of 0.0/20 suggests Pfizer's current filing-period operations do not map to the macro growth themes the model tracks, which may limit its appeal to growth-oriented research profiles and narrows its score ceiling under the current model framework.
Risk Profile
Medium RiskThe Medium risk rating reflects Pfizer's position as a large, diversified pharmaceutical company with substantial assets and established cash flows, but acknowledges real near-term uncertainty around revenue trajectory, dividend sustainability as reflected in the low FCF payout coverage score, and the execution risks associated with integrating a major acquisition while navigating post-pandemic demand normalization. This is not a risk profile driven by financial distress, but rather by operational and strategic transition risk at a critical inflection point for the business.
Key Catalysts to Watch
The most important factors to monitor in future filings are the trajectory of Pfizer's non-COVID product revenues — particularly from the oncology and immunology portfolios — and whether free cash flow generation improves sufficiently to restore confidence in dividend coverage, as these two dynamics would most directly shift the growth and dividend sub-scores that are currently limiting the composite model score.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.